Progression of left ventricular mass is associated with clinical events in key subgroups of Fabry disease: Analyses from the Fabry Registry

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F25%3A10501972" target="_blank" >RIV/00064165:_____/25:10501972 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/25:10501972

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=FRp4YZObhK" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=FRp4YZObhK</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ymgme.2025.109200" target="_blank" >10.1016/j.ymgme.2025.109200</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Progression of left ventricular mass is associated with clinical events in key subgroups of Fabry disease: Analyses from the Fabry Registry

Popis výsledku v původním jazyce

Introduction: Cardiovascular complications are the primary cause of morbidity and mortality in Fabry disease. Despite disease-specific and adjuvant treatments, gaps in care exist. Cardiac imaging facilitates the understanding of disease progression, however data on the clinical relevance of imaging endpoints in Fabry disease are scant. Therefore, we evaluated the association between left ventricular mass index (LVMi) measured via echocardiography and risk of subsequent clinical events. Methods: Adult patients from the Fabry Registry treated with enzyme replacement therapy, with echocardiography measurements and no prior kidney events were analyzed. Composite clinical events included cardiac, cerebrovascular, and kidney events, or death. Cox proportional hazard models were used to estimate hazard ratios (HR) and 95 % confidence intervals (CI) for the association between (1) baseline LVMi and (2) LVMi progression (i.e., slopes) with the risk of subsequent clinical events. Results: Baseline LVMi analysis included 809 patients (53.1 % females) with median age at diagnosis [25&lt;sup&gt;th&lt;/sup&gt;, 75&lt;sup&gt;th&lt;/sup&gt; percentile]: 39.5 years [26.7, 52.2]) who had 248 clinical events, including 170 cardiac events, over 4752 and 5128 person-years, respectively. Higher baseline LVMi was associated with greater risk of composite clinical and cardiac events (adjusted HR per 10 % higher baseline LVMi: 1.09 [95 % CI: 1.04-1.13; p &lt; 0.001] and 1.11 [95 % CI: 1.06-1.17; p &lt; 0.0001], respectively). LVMi slope analysis included 377 patients with median 3-year LVMi slope [25&lt;sup&gt;th&lt;/sup&gt;, 75&lt;sup&gt;th&lt;/sup&gt; percentile] of -0.5 g/m&lt;sup&gt;2&lt;/sup&gt;/year [-7.8, 7.2]; and evaluated 86 composite clinical events and 57 cardiac events, over 1899 and 2028 person-years, respectively. Increasing LVMi slope was associated with higher incidence of clinical events in key subgroups including in those with the classic Fabry phenotype, those with left ventricular hypertrophy (LVH) at baseline, those with pre-baseline clinical events and in patients with history of hypertension; adjusted HR per 10 g/m&lt;sup&gt;2&lt;/sup&gt;/year increase in LVMi slope ranged from 1.16 to 1.64 (p &lt; 0.05). Conclusions: Our study quantifies the biologically plausible association between LVMi and its progression with composite clinical events, including in key subgroups of Fabry patients.

Název v anglickém jazyce

Progression of left ventricular mass is associated with clinical events in key subgroups of Fabry disease: Analyses from the Fabry Registry

Popis výsledku anglicky

Introduction: Cardiovascular complications are the primary cause of morbidity and mortality in Fabry disease. Despite disease-specific and adjuvant treatments, gaps in care exist. Cardiac imaging facilitates the understanding of disease progression, however data on the clinical relevance of imaging endpoints in Fabry disease are scant. Therefore, we evaluated the association between left ventricular mass index (LVMi) measured via echocardiography and risk of subsequent clinical events. Methods: Adult patients from the Fabry Registry treated with enzyme replacement therapy, with echocardiography measurements and no prior kidney events were analyzed. Composite clinical events included cardiac, cerebrovascular, and kidney events, or death. Cox proportional hazard models were used to estimate hazard ratios (HR) and 95 % confidence intervals (CI) for the association between (1) baseline LVMi and (2) LVMi progression (i.e., slopes) with the risk of subsequent clinical events. Results: Baseline LVMi analysis included 809 patients (53.1 % females) with median age at diagnosis [25&lt;sup&gt;th&lt;/sup&gt;, 75&lt;sup&gt;th&lt;/sup&gt; percentile]: 39.5 years [26.7, 52.2]) who had 248 clinical events, including 170 cardiac events, over 4752 and 5128 person-years, respectively. Higher baseline LVMi was associated with greater risk of composite clinical and cardiac events (adjusted HR per 10 % higher baseline LVMi: 1.09 [95 % CI: 1.04-1.13; p &lt; 0.001] and 1.11 [95 % CI: 1.06-1.17; p &lt; 0.0001], respectively). LVMi slope analysis included 377 patients with median 3-year LVMi slope [25&lt;sup&gt;th&lt;/sup&gt;, 75&lt;sup&gt;th&lt;/sup&gt; percentile] of -0.5 g/m&lt;sup&gt;2&lt;/sup&gt;/year [-7.8, 7.2]; and evaluated 86 composite clinical events and 57 cardiac events, over 1899 and 2028 person-years, respectively. Increasing LVMi slope was associated with higher incidence of clinical events in key subgroups including in those with the classic Fabry phenotype, those with left ventricular hypertrophy (LVH) at baseline, those with pre-baseline clinical events and in patients with history of hypertension; adjusted HR per 10 g/m&lt;sup&gt;2&lt;/sup&gt;/year increase in LVMi slope ranged from 1.16 to 1.64 (p &lt; 0.05). Conclusions: Our study quantifies the biologically plausible association between LVMi and its progression with composite clinical events, including in key subgroups of Fabry patients.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Molecular Genetics and Metabolism

ISSN

1096-7192

e-ISSN

1096-7206

Svazek periodika

146

Číslo periodika v rámci svazku

1-2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

12

Strana od-do

109200

Kód UT WoS článku

001583882500001

EID výsledku v databázi Scopus

2-s2.0-105012965918